These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 7476891)

  • 21. DNA interaction and dual topoisomerase I and II inhibition properties of the anti-tumor drug prodigiosin.
    Montaner B; Castillo-Avila W; Martinell M; Ollinger R; Aymami J; Giralt E; Pérez-Tomás R
    Toxicol Sci; 2005 Jun; 85(2):870-9. PubMed ID: 15788728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
    Riou JF; Fossé P; Nguyen CH; Larsen AK; Bissery MC; Grondard L; Saucier JM; Bisagni E; Lavelle F
    Cancer Res; 1993 Dec; 53(24):5987-93. PubMed ID: 8261412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells.
    Bonjean K; De Pauw-Gillet MC; Defresne MP; Colson P; Houssier C; Dassonneville L; Bailly C; Greimers R; Wright C; Quetin-Leclercq J; Tits M; Angenot L
    Biochemistry; 1998 Apr; 37(15):5136-46. PubMed ID: 9548744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110.
    Yoshinari T; Yamada A; Uemura D; Nomura K; Arakawa H; Kojiri K; Yoshida E; Suda H; Okura A
    Cancer Res; 1993 Feb; 53(3):490-4. PubMed ID: 8381047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the bifunctional antitumor intercalator ditercalinium on DNA in mouse leukemia L1210 cells and DNA topoisomerase II.
    Markovits J; Pommier Y; Mattern MR; Esnault C; Roques BP; Le Pecq JB; Kohn KW
    Cancer Res; 1986 Nov; 46(11):5821-6. PubMed ID: 3019538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
    Shuai L; Wang S; Zhang L; Fu B; Zhou X
    Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Topoisomerases I: new targets for the treatment of cancer and mechanisms of resistance].
    Pourquier P; Pommier Y
    Bull Cancer; 1998 Dec; Spec No():5-10. PubMed ID: 9932078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interaction model for anthracycline activity against DNA topoisomerase II.
    Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
    Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability.
    Kong XB; Rubin L; Chen LI; Ciszewska G; Watanabe KA; Tong WP; Sirotnak FM; Chou TC
    Mol Pharmacol; 1992 Feb; 41(2):237-44. PubMed ID: 1311406
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
    Antony S; Agama KK; Miao ZH; Hollingshead M; Holbeck SL; Wright MH; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Mol Pharmacol; 2006 Sep; 70(3):1109-20. PubMed ID: 16798938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA topoisomerase II is the molecular target of bisdioxopiperazine derivatives ICRF-159 and ICRF-193 in Saccharomyces cerevisiae.
    Ishida R; Hamatake M; Wasserman RA; Nitiss JL; Wang JC; Andoh T
    Cancer Res; 1995 Jun; 55(11):2299-303. PubMed ID: 7757979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a)quinolinium with DNA topoisomerases: a possible-mechanism for its biological activity.
    Báez A; Riou JF; Le Pecq JB; Riou G
    Mol Pharmacol; 1990 Mar; 37(3):377-82. PubMed ID: 2156151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The bis(naphthalimide) DMP-840 causes cytotoxicity by its action against eukaryotic topoisomerase II.
    Nitiss JL; Zhou J; Rose A; Hsiung Y; Gale KC; Osheroff N
    Biochemistry; 1998 Mar; 37(9):3078-85. PubMed ID: 9485461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl(2)(C(6)H(6))(dmso)].
    Vashisht Gopal YN; Konuru N; Kondapi AK
    Arch Biochem Biophys; 2002 May; 401(1):53-62. PubMed ID: 12054487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221.
    Creighton-Gutteridge M; Cardellina JH; Stephen AG; Rapisarda A; Uranchimeg B; Hite K; Denny WA; Shoemaker RH; Melillo G
    Clin Cancer Res; 2007 Feb; 13(3):1010-8. PubMed ID: 17289897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.